

FORM 11

NOTICE OF PROPOSED STOCK OPTION GRANT

Name of Listed Issuer: Entheon Biomedical Corp. (the "Issuer").

Trading Symbol: ENBI

Date: July 30, 2021

1. New Options Granted:

Date of Grant: July 30, 2021; July 29, 2021

Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Date of Grant	Expiry Date	No. of Options Granted in Past 12 Months
Consultant	No	100,000	\$0.355	July 30, 2021	July 30, 2026	N/A
Consultant	No	100,000	\$0.355	July 30, 2021	July 30, 2026	N/A
Consultant	No	200,000	\$0.33	July 29, 2021	July 29, 2026	N/A

Total Number of optioned shares proposed for acceptance: 400,000

Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares ⁽¹⁾	Exercise Price	Original Date of Grant	Expiry Date
Officers, Directors & Consultants	3,175,000	\$0.71	Dec 3, 2020	Dec 3, 2025
Consultant	50,000	\$0.71	Mar 19, 2021	Mar 19, 2026

(1) Set out number of optioned shares for each grant with different terms.

3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held.

N/A

- (b) State the date of the news release announcing the grant of options.

N/A

- (c) State the total issued and outstanding share capital at the date of grant or amendment.

59,039,266

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.

6.1%

- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan.

2,278,927

- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.

\$0.53

- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer.

N/A

4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated: July 30, 2021

Brandon Schwabe
Name of Director or Senior
Officer

"Brandon Schwabe"
Signature

CFO
Official Capacity